Ipsen disclosed that Bylvay failed a Phase 3 study for biliary atresia, a serious liver disease that leads the bile ducts to become blocked in babies.
Ipsen disclosed that Bylvay failed a Phase 3 study for biliary atresia, a serious liver disease that leads the bile ducts to become blocked in …
Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.
Three years after gaining three liver disease assets in its $952 million buyout of Alb | Three years after gaining three liver…
GSK has shared detailed results from a pair of late-stage trials testing a chronic hepatitis B treatment originally developed by…
The committee reported cases of hematologic malignancies in a follicular lymphoma study dubbed SYMPHONY-1.
The planned acquisition of Kartos Therapeutics would hand Ipsen a late-stage asset for myelofibrosis. Elsewhere, Sobi hit a…
Lilly pays up to $1B for AlzeCure's small-molecule Alzheimer's candidate; Bial drops Parkinson's drug after Phase 2b miss;…
Regeneron Pharmaceuticals’ LAG-3 inhibitor called fianlimab has flunked a late-stage skin cancer trial, marking yet another blow…
